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Connective tissue diseases (CTDs) are a heterogeneous group of disorders that share certain clinical presentations
and a disturbed immunoregulation, leading to autoantibody production. Subclinical or overt renal manifestations
are frequently observed and complicate the clinical course of CTDs. Alterations of kidney function in Sjögren
syndrome, systemic scleroderma (SSc), auto-immune myopathies (dermatomyositis and polymyositis), systemic
lupus erythematosus (SLE), antiphospholipid syndrome nephropathy (APSN) as well as rheumatoid arthritis (RA) are
frequently present and physicians should be aware of that.
In SLE, renal prognosis significantly improved based on specific classification and treatment strategies adjusted to
kidney biopsy findings. Patients with scleroderma renal crisis (SRC), which is usually characterized by severe
hypertension, progressive decline of renal function and thrombotic microangiopathy, show a significant benefit of
early angiotensin-converting-enzyme (ACE) inhibitor use in particular and strict blood pressure control in general.
Treatment of the underlying autoimmune disorder or discontinuation of specific therapeutic agents improves
kidney function in most patients with Sjögren syndrome, auto-immune myopathies, APSN and RA.
In this review we focus on impairment of renal function in relation to underlying disease or adverse drug effects
and implications on treatment decisions.
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Impairment of renal function is present to some extent
in many connective tissue diseases (CTDs) with variable
occurrence in Sjögren syndrome [1,2], roughly 5% in
systemic scleroderma (SSc) [3], rarely in inflammatory
auto-immune myopathies, a prevalence of approximately
50% in systemic lupus erythematosus (SLE) [4], and rare
occurrence in antiphospholipid syndrome [5] and rheuma-
toid arthritis (RA). Apart from that, kidney involvement
can be of significant prognostic value and often entails
specific therapeutic implications.
Lymphocytic infiltration, leading to acute or chronic
tubulointerstitial nephritis, is the predominant renal
pathology in Sjögren syndrome [2,6,7]. Scleroderma
renal crisis (SRC) is a severe, potentially life-threatening
complication in scleroderma and is, in most cases,
accompanied by malignant hypertension, overexpression* Correspondence: gert.mayer@i-med.ac.at
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distribution, and reproduction in any mediumof pro-inflammatory cytokines and rapid decline of renal
function [8-10]. In rare cases patients present with
normotensive SRC, which is associated with a poorer
prognosis and a prompter need for dialysis [11-13].
Early commencement of angiotensin-converting-enzyme
(ACE)-inhibitors and other antihypertensive drugs is
mandatory in the management of SRC. Rhabdomyolysis
with acute tubular necrosis or glomerular disorders, includ-
ing minimal change disease, membranous nephropathy,
IgA nephropathy or diffuse proliferative glomeruloneph-
ritis, has been reported in patients with auto-immune
myopathies [14,15].
Lupus nephritis is one of the most severe organ
manifestations of the disease and, depending on biopsy
findings, needs aggressive immunosuppressive therapy.
The histopathologic classification of lupus nephritis
guides therapeutic interventions with the aim to reduce
proteinuria and preserve kidney function. Renal manifest-
ation in primary and secondary antiphospholipid syndrome
(APS) is a well-described complication, frequently leadingd Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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renal function [5,16]. Patients with RA are at an increased
risk of developing secondary amyloidosis due to long-
lasting chronic inflammation as well as mesangial
glomerulonephritis and membranous nephropathy related
to specific drugs [17]. Table 1 summarizes specific kidney




Primary Sjögren syndrome (PSS) is an autoimmune
disorder of hitherto unknown origin which is characterized
by polyclonal B-cell activation as well as lymphocytic
infiltration of the exocrine glands, resulting in kerato-
conjunctivitis sicca (dry eyes disease) and/or xerostomia
(dry mouth disease) [18]. In addition, extraglandular
manifestations of PSS can affect organ systems, such as
the lungs, blood vessels, skin, the gastrointestinal tract,
central and peripheral nervous system, muscular skeletal
apparatus and the kidney [19,20]. Affected patients are at
increased risk of developing non-Hodgkin’s lymphoma, in
particular lymphomas of B-cell origin [21]. Secondary
Sjögren syndrome is associated with other rheumatic
disorders, such as RA, SLE, SSc and others. Renal disease
with PSS is reported to occur in 4.2% [1] to 67% [2] of
patients. The variation is considered to be associated withTable 1 Overview of kidney biopsy findings in patients with c
Renal biopsy findings Con
Tubulointerstitial nephritis (TIN) Sjög
Mesangial proliferative glomerulonephritis/IgA nephropathy Sjög
Syste
Focal segmental glomerulosclerosis (FSGS) Sjög
Anti
Cryoglobulinemic membrano-proliferative glomerulonephritis Sjög




Secondary renal amyloidosis Sjög
Thrombotic microangiopathy Anti








Focal proliferative glomerulonephritis Rheu
Crescentic GN with FSGS Poly
C3 nephropathy Antithe different diagnostic criteria used, different study designs
and small cohorts examined as well as selection bias.Histopathology/kidney involvement
Acute or chronic tubulointerstitial nephritis (TIN) with
defects in tubular function is the predominant lesion in
biopsy-proven renal involvement [2,6]. Distal (type I)
renal tubular acidosis (RTA) is the most common clinical
finding, leading to mild symptoms but also to potentially
life-threatening complications, such as hypokalemic
paralysis [22]. Albeit considered to be rare, proximal
(type II) RTA has been reported in some cases [6,23].
Moreover, glomerular disease, such as cryoglobulinemic
membrano-proliferative glomerulonephritis, focal seg-
mental glomerulosclerosis (FSGS), mesangial proliferative
glomerulonephritis, membranous nephropathy and min-
imal change disease have been reported [2,6,7,24]. A single
case of long-lasting TIN in a patient with PSS led to a
secondary (AA) amyloidosis with, consequently, renal
failure and nephrotic syndrome [18]. Interestingly, in
one study SSA/Ro, SSB/La and rheumatoid factor, as
well as hypergammaglobulinemia, were detected in all
subjects with biopsy-proven renal involvement [6]. In
another cohort, all patients with distal RTA had positive
anti-nuclear antibodies and either SSA or SSB antibodies
were detected in 85.7% of them [25].onnective tissue diseases
nective tissue disease
ren syndrome [2,6,7], Rheumatoid arthritis [17]
ren syndrome [2], Polymyositis [46,50,51], Dermatomyositis [58],
mic lupus erythematosus [80], Rheumatoid arthritis [17,138]
ren syndrome [6], Systemic lupus erythematosus [81],
phospholipid syndrome [124], Rheumatoid arthritis [139]
ren syndrome [2,6]
ren syndrome [6,24], Polymyositis [52], Systemic lupus erythematosus
3], Antiphospholipid syndrome [124], Rheumatoid arthritis [17]
ren syndrome [2,6], Polymyositis [53], Dermatomyositis [55-57], Class V lupus
ritis [78], Antiphospholipid syndrome [124], Rheumatoid arthritis [17,133-135]
ren syndrome [18], Rheumatoid arthritis [17,136,137]
phospholipid syndrome [119,123], Scleroderma renal crisis [13]
atomyositis [49]
mic lupus erythematosus [81]
mic lupus erythematosus [79]
I to VI lupus nephritis [78], drug-induced proliferative lupus nephritis [142]
phospholipid syndrome [125], Rheumatoid arthritis [140]
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Treatment with glucocorticoids should be initiated as first
line therapy in patients with PSS and renal involvement
since a good response to early treatment has been reported
[6,26]. In addition, long-term bicarbonate and/or electrolyte
supplementation should be commenced in a majority of
patients to prevent life-threatening complications [26].
Besides corticosteroids, alternative immunosuppressive
therapies (hydroxychloroquine, rituximab, cyclophos-
phamide) should be prescribed based on kidney biopsy
findings as well as comorbidities. It was shown that
renal function maintained or improved during a median
follow-up period of 38 months after treatment with
immunosuppressive drugs [6].
Conclusion
Corticosteroids are a mainstay in the treatment of TIN.
Further histologic findings require specifically-tailored
immunosuppression and most importantly, supplementa-




SSc is a CTD characterized by deposition and overpro-
duction of extracellular matrix proteins and collagen,
resulting in tissue fibrosis and, subsequently, tissue
dysfunction. Affected organs and tissues include the
skin, gastrointestinal tract, heart, lungs and kidneys.
Involvement of the vascular system generally results in
the development of Raynaud’s phenomenon early in the
disease course. Consecutively, severe clinical manifesta-
tions of vascular dysfunction can be observed in some
patients leading to pulmonary fibrosis and pulmonary
artery hypertension, esophageal motility dysfunction,
watermelon stomach, cardiac involvement, as well as
scleroderma renal crisis (SRC) [27-29]. Epithelial to
mesenchymal transition (EMT), a condition that conveys
a phenotypic conversion from differentiated epithelial
cells to matrix-producing fibroblasts and myofibroblasts,
is recognized as a crucial part of the development of
tissue fibrogenesis [30,31]. Several growth factors, such
as transforming growth factor ß (TGFß) [8], connective
tissue growth factor (CTGF) [9], as well as other
mediators, such as endothelin-1 [10], are involved in
tissue remodelling. SRC occurs in roughly 5% of patients
with SSc [3]. Several risk factors with a predictive value
were established: duration of SSc onset of less than four
years, higher incidence of progressive skin thickening
prior to renal involvement, new development of anemia
and cardiac involvement (pericardial effusion or congestive
heart failure) [32]. Detection of anti-RNA polymerase III
antibodies displays a strong risk marker for the presence
of SRC, whereas the presence of anti-topoisomerase andanti-centromere antibodies in scleroderma indicates a
favorable disease course [33]. In addition, a case control
study revealed a significant positive association between
long-lasting high-dose corticosteroid treatment (≥15 g/d)
and the onset of SRC [34]. On average, in 10% of patients,
SRC occurs in the absence of hypertension. Normotensive
renal crisis was more frequently present in patients treated
with high doses of corticosteroids and in patients with
redundant microangiopathic hemolytic anemia and
thrombocytopenia in consequence to the underlying
disease [11]. In addition, normotensive renal failure in
SSc was associated with a higher mortality rate and an
earlier need for dialysis treatment [11-13]. Blood pressure
levels greater than 150/90 mmHg were observed in almost
90% of patients experiencing SRC. Hypertensive SRC is
accompanied by clinical signs of malignant hypertension
with left ventricular failure, hypertensive encephalopathy
and arrhythmia [12].
Histopathology/kidney involvement
Diagnosis of SRC is confirmed by renal biopsy, which
shows a thrombotic microangiopathic process, particularly
affecting small vessels. Vascular changes are accompanied
by thrombosis, accumulation of myxoid material and later
in the disease course, development of onion-skin lesions
and/or fibrointimal sclerosis [13]. Furthermore, one has to
keep in mind that ANCA-associated vasculitis is a rare
complication of SSc and in general presents with antibodies
directed against myeloperoxidase and p-ANCA [35].
Therapy
Early use of ACE inhibitors, on the basis of most experience
in particular captopril, is undoubtedly a cornerstone in the
management of hypertensive SRC. Immediate use with a
progressive increase of ACE inhibitor dosage, even in the
presence of deteriorating kidney function, is considered to
prevent or even reverse renal failure [36,37]. Additional
antihypertensive therapy (calcium channel blockers, alpha/
beta-adrenoreceptor antagonists and/or minoxidil) is
mandatory when blood pressure is insufficiently controlled
[28,36]. Recent findings suggest that dialysis was required
in more than 50% of patients either in case of volume
overload together with renal deterioration or to control
blood pressure due to therapy-resistant hypertension
[3,12]. Discontinuation of dialysis treatment could be
accomplished in 16 to 55% patients with SRC [3,37]. After
a stable disease course with continuous dialysis, renal
transplantation should be considered when contraindi-
cations are ruled out. In a cohort of 260 patients with
SSc who underwent kidney transplantation, the overall
five-year graft survival rate was 56.7%. Among those,
the recurrence of disease after transplantation was 6.7%
in a report of the United Network of Organ Sharing
(UNOS) [38]. Based on the finding that cyclosporine A
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patients with SSc [39], calcineurin inhibitors are not
generally recommended as immunosuppressants after
kidney transplantation.
Conclusion
Renal involvement in SSc is often accompanied by
progressive renal failure and rapid initiation of therapeutic
interventions is mandatory. Blood pressure control, in
particular with ACE-inhibitors and additional antihy-
pertensive medication, is essential. If blood pressure is
not adjustable or the patient shows signs of fluid overload,
dialysis should be considered early in the disease course.
Discontinuation of dialysis was reported in some patients.
In patients with chronic hemodialysis and renal trans-
plantation, a calcineurin-inhibitor free immunosuppressive
regimen might be chosen.
Dermatomyositis and polymyositis
Introduction
Auto-immune myopathies, namely dermatomyositis
(DM) and polymyositis (PM), share common clinical
features, such as proximal muscle weakness, muscle
inflammation, presence of autoantibodies, elevated
muscle enzymes, electromyographic alterations and
extra muscular manifestations. Despite clinical similar-
ities, both differ regarding muscle biopsy findings and
DM is associated with cutaneous involvement. The
presence of a heliotrope rash, which is characterized by
a violaceous skin discoloration around the eyes, and
Gottron’s sign (erythematous papules with involvement
of joints) are pathognomonic for DM [40,41]. Both entities
are associated with concurrent incidence of neoplasms. In
large cohorts, malignancies were detected in 9.4 to 32% of
patients in DM and in 4.4 to 17% in PM patients [42-45]
with a predominance of adenocarcinomas [45].
Histopathology/kidney involvement
Two types of renal involvement have been described in
patients with PM/DM. First, rhabdomyolysis with release
of myoglobin can lead to acute tubular necrosis with
deterioration of renal function [14,15]. Second, several
reports revealed the occurrence of chronic glomerulo-
nephritis in patients with PM/DM [14,46-49]. In PM,
mesangial proliferative glomerulonephritis represents
the leading glomerular lesion [46,50,51]. Moreover,
other biopsy specimens showed lipoid nephrosis with
FSGS [52], membranous nephropathy [53] and cres-
centic glomerulonephritis with FSGS [54]. In contrast,
the predominant finding in DM with renal involvement
is membranous nephropathy [55-57]. Nevertheless,
both mesangial proliferative glomerulonephritis [58]
and diffuse proliferative glomerulonephritis [49] have
been reported in single case reports.Therapy
High-dose oral corticosteroids are the cornerstone of
DM/PM therapy. Moreover, the addition of immunosup-
pressive drugs, such as azathioprine (AZA) or cyclo-
phosphamide (CYC), as well as anti-malaria medication
in DM and methotrexate, CYC, intravenous immuno-
globulins and CSA in PM has been reported to improve
the renal outcome in DM/PM [14,49,55-58]. In contrast
to these reports, one patient progressed to end-stage
renal disease despite immunosuppressive treatment [59].
Follow-up of the patients with DM revealed a high
mortality rate due to cancer or multi-organ failure, while
mortality in PM was high due to acute rhabdomyolysis
followed by severe hyperkalemia and metabolic acidosis
in a case report [14].
Conclusion
Management of patients with auto-immune myopathies
and renal involvement require special caution, because
disease-related mortality due to rhabdomyolysis and
hyperkalemia is greatly feared. Special therapeutic inter-
vention with immunosuppression should be tailored to
the underlying histology. In most cases, corticosteroids
might be effective as one therapeutic component.
Systemic lupus erythematosus
Introduction
SLE depicts a remarkable complex autoimmune disease
with considerable heterogeneity in clinical manifesta-
tions and disease course. Classification of SLE was last
edited by the American College of Rheumatology (ACR)
in 1997 [60] (Table 2). Earlier diagnosis, more intensive
treatment regimens and diverse alternative strategies
and possibilities to treat co-morbidities have contributed
to improvement of prognosis [61]. Negative predictive
factors with respect to survival include male gender,
positive lupus anticoagulant, glomerulonephritis and
“severe” onset of SLE [62]. The incidence is much higher in
young woman and the prevalence is two- to four-fold
greater in non-Caucasian populations [63]. Genetic,
environmental and hormonal factors have been identified
as possible risk factors for developing SLE [64,65].
Autoantibodies are directed against various nuclear
antigens, in particular against chromatin components,
such as nucleosomes, histones, anti-nuclear antibodies
(ANA), double-stranded DNA antibodies (dsDNA) and
ribonucleoproteins. Recently, it was suggested that the
nucleosome might be the driving autoantigen in SLE.
This hypothesis is supported by the finding that
glomerular deposition of anti-dsDNA antibodies in lupus
nephritis is mediated by nucleosomes [66,67]. The
kidneys are a major source of autoantibody-producing
plasma cells in lupus nephritis and these differentiated
plasma cells are frequently observed in patients with
Table 2 Revised criteria of the American College of Rheumatology
1. Malar rash Fixed erythema, flat or raised, over the malar eminences, tending to spare the nasolabial folds
2. Discoid rash Erythematous raised patches with adherent keratotic scaling and follicular plugging; atrophic
scarring may occur in older lesions
3. Photosensitivity Skin rash as a result of unusual reaction to sunlight, by patient history or physician observation
4. Oral ulcers Oral or nasopharyngeal ulceration, usually painless, observed by physician
5. Non-erosive arthritis Involving two or more peripheral joints, characterized by tenderness, swelling or effusion
6. Pleuritis/Pericarditis 1. Pleuritis, convincing history of pleuritic pain or rubbing heard by a physician or evidence of pleural effusion, or
2. Pericarditis, documented by electrocardiogram or rub or evidence of pericardial effusion
7. Renal disorder 1. Persistent proteinuria >0.5 grams per day or more than 3+ on urine dipstick testing, or
2. Cellular casts (may be red cell, hemoglobin, granular, tubular, or mixed)
8. Neurologic disorder 1. Seizures, in the absence of offending drugs or known metabolic derangements; for example,
uremia, ketoacidosis, or electrolye imbalance, or
2. Psychosis, in the absence of offending drugs or known metabolic derangements; for example,
uremia, ketoacidosis, or electrolyte imbalance
9. Hematologic disorder 1. Hemolytic anemia with reticulocytosis, or
2. Leukopenia <4.000/mm3 on ≥2 occasions, or
3. Lymphopenia <1.500/mm3 on ≥2 occasions, or
4. Thrombocytopenia <100.000/mm3 in the absence of offending drugs
10. Immunologic disorder 1. Anti-DNA: antibody to native DNA in abnormal titer, or
2. Anti-Sm: presence to antibody of SM nuclear antigen, or
3. Positive finding of antiphospholipid antibodies on:
● An abnormal serum level of IgG or IgM anticardiolipin antibodies
● A positive test result for lupus anticoagulant using a standard method, or
● A false-positive test result for at least six months confirmed by Treponema pallidum
immobilization or fluorescent treponemal antibody absorption test
11. Positive anti-nuclear antibody An abnormal titer of anti- nuclear antibody by immunofluorescence or an equivalent assay at any point
in time and in the absence of drugs
Diagnosis of systemic lupus erythematosus requires at least 4 out of 11 criteria [60]. Reprint permission was obtained from John Wiley and Sons, Inc.
Kronbichler and Mayer BMC Medicine 2013, 11:95 Page 5 of 14
http://www.biomedcentral.com/1741-7015/11/95severe renal involvement (mainly classes III through V),
potentially acting in amplifying the renal disease course
[68]. Additional autoantibodies include anti-Smith (Sm)
antibodies with a high specificity for SLE, while SSA and
SSB are present in other CTDs as well [69]. Complement
levels are frequently reduced in patients with active
disease. Genetic complete complement deficiencies can
resemble a SLE-like disease [70]. Levels of complement
C3 and C4 correlate with the overall disease activity.
Patients with active lupus nephritis had significantly lower
levels of C3 and C4 compared to patients with inactive
lupus nephritis [71]. Serum C3 has generally higher sensi-
tivity than serum C4, but both tests have only modest
specificity for active lupus nephritis [72]. Assessment of
the relationship between serum levels of C3 or C4 and
renal flares revealed that C4 is critical for initiating a renal
flare, while C3 activation is involved in the actual tissue
damage [73]. Antibodies directed against C1q were
detected in all patients with active nephritis in a large
cohort [74]. Moreover, anti-C1q antibodies showed the
strongest association with proteinuria among potential
biomarkers and were significantly correlated with RenalActivity Score [75]. However, contradictory to these reports,
in a cohort of 126 patients, anti-C1q antibodies were not
significantly associated with active lupus nephritis [76].
Histopathology/kidney involvement
Involvement of the kidney in the natural history of
disease is present in a majority of patients and is supposed
to appear in almost 50% in the first year of diagnosis [4].
Recent findings even suggest a higher incidence, since a
considerable proportion of patients with SLE have silent
lupus nephritis. Diagnosis in the latter group was signifi-
cantly earlier compared to the overt lupus nephritis group
and urinary sediment as well as renal function tests were
normal [77]. Renal biopsy findings are categorized
according to the current classification of lupus nephritis,
which was published on behalf of the International Society
of Nephrology (ISN)/Renal Pathology Society (RPS) [78]
(Table 3). However, one should be aware that other
glomerular changes, such as collapsing glomerulopathy
[79], IgA nephropathy [80], FSGS, IgM nephropathy [81],
minimal change disease [82]/glomerular podocytopathy
[83] can occur as well and alterations in kidney function
Table 3 Revised classification lupus nephritis according to the International Society of Nephrology/Renal Pathology
Society (ISN/RPS) 2003 [78]
Class I Minimal mesangial lupus nephritis
Normal glomeruli by light microscopy, but mesangial immune deposits by immunofluorescence
Class II Mesangial proliferative lupus nephritis
Purely mesangial hypercellularity of any degree or mesangial matrix expansion by light microscopy,
with mesangial immune deposits
May be a few isolated subepithelial deposits visible by immunofluorescence or electron microscopy,
but not by light microscopy
Class III Focal lupus nephritis
Active or inactive focal, segmental or global endo- or extracapillary glomerulonephritis involving <50%
of all glomeruli, typically with focal subendothelial immune deposits, with or without mesangial alterations
Class III (A) Active lesions: focal proliferative lupus nephritis
Class III (A/C) Active and chronic lesions: focal proliferative and sclerosing lupus nephritis
Class III (C) Chronic inactive lesions with glomerular scars: focal sclerosing lupus nephritis
Class IV Diffuse lupus nephritis
Active or inactive diffuse, segmental or global endo- or extracapillary glomerulonephritis involving ≥50%
of all glomeruli, typically with diffuse subendothelial immune deposits, with or without mesangial
alterations. This class is divided into diffuse segmental (IV-S) lupus nephritis when ≥50% of the involved
glomeruli have segmental lesions, and diffuse global (IV-G) lupus nephritis when ≥50% of the involved
glomeruli have global lesions. Segmental is defined as a glomerular lesion that involves less than half of
the glomerular tuft. This class includes cases with diffuse wire loop deposits but with little or no
glomerular proliferation
Class IV-S (A) Active lesions: diffuse segmental proliferative lupus nephritis
Class IV-G (A) Active lesions: diffuse global proliferative lupus nephritis
Class IV-S (A/C) Active and chronic lesions: diffuse segmental proliferative and sclerosing lupus nephritis
Active and chronic lesions: diffuse global proliferative and sclerosing lupus nephritis
Class IV-S (C) Chronic active lesions with scars: diffuse segmental sclerosing lupus nephritis
Class IV-G (C) Chronic inactive lesions with scars: diffuse global sclerosing lupus nephritis
Class V Membranous lupus nephritis
Global or segmental subepithelial immune deposits or their morphologic sequelae by light microscopy
and by immunofluorescence or electron microscopy, with our without mesangial alterations
Class V lupus nephritis may occur in combination with class III or IV in which case both will be diagnosed
Class V lupus nephritis show advanced sclerosis
Class VI Advanced sclerosis lupus nephritis
≥90% of glomeruli globally sclerosed without residual activity
Reprint permission was obtained from the Journal of the American Society of Nephrology.
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well as type I and IV RTA [85], have also been reported.
Therapy
In general, use of ACE inhibitors significantly reduced
the development of proteinuria and/or biopsy-proven
lupus nephritis and was associated with a decreased risk
of disease activity [86]. Concomitant use of antimalarial
drugs (chloroquine and hydroxychloroquine) at diagnosis
of lupus nephritis reduced the risk of progression to
end-stage renal failure and frequency of hypertension [87].
Specific treatment follows the class of lupus nephritis,
which is defined by the revised ISN criteria. Class I and
class II require no therapy directed at the kidney in conse-
quence of good long-term renal outcome [88]. In contrast,high-dose steroid therapy rapidly resolved nephrotic
syndrome in a majority of SLE patients with minimal
change disease either in the absence or with underlying
class II lupus nephritis based on renal biopsy findings
[82,83]. Immunosuppressive treatment is required in
the management of class III (focal), class IV (diffuse)
and class V (membranous nephropathy) lupus nephritis
and usually consists of high dose glucocorticoid therapy
along with intravenous CYC or mycophenolate mofetil
(MMF) as induction therapy. The Euro Lupus Nephritis
Trial compared low dose CYC (fortnightly, at a fixed
dose of 500 mg, with a cumulative dose of 3 g) with the
previously established high dose CYC (NIH) regimen
(mean cumulative dose 8.5 g). Both strata were followed by
AZA as remission-maintaining treatment. Renal outcome
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group had fewer severe infections, even though the differ-
ence was not statistically significant [89]. Reports from this
trial with a 10-year duration of follow-up confirmed the
efficacy of the Euro Lupus regimen [90]. Since a majority
of the subjects were white in this trial, these results might
be less applicable to other ethnicities. In a more diversified
cohort (>50% blacks) MMF (mean daily dosage 2.68 g) has
been reported to be superior as induction therapy when
compared to monthly CYC (0.5 g to 1 g/m2) in patients
with class III through V lupus nephritis [91]. A further
large, multi-center trial in a balanced cohort with respect
to ethnicities designed to show superiority of MMF
(mean daily dosage 2.47 g) to CYC failed to meet the
primary end point. Both treatment arms achieved
virtually identical rates of complete and partial remission.
Furthermore, no significant difference with regard to
severe adverse events or infections was reported [92].
Response to MMF as induction treatment in pure class
V (membranous nephropathy) lupus nephritis in patients
with diverse racial background appeared to show no differ-
ence in comparison to CYC [93]. Patients (>60% black)
with class V lupus nephritis showed a better response
regarding induction of remission after CSA when compared
to CYC, whereas relapse of nephrotic syndrome occurred
more frequently in patients with prior CSA therapy [94]. In
a small cohort, multi-target therapy (MMF and tacrolimus)
in patients with class IV and class V lupus nephritis
revealed a higher rate of complete remission with a good
tolerability when compared to intravenous CYC [95].
Following induction therapy, long-term immunosuppres-
sion is mandatory to avoid severe flares and to maintain
stabilization of disease activity. Thus, immunosuppressants
with a favorable safety profile and good efficacy are
mandatory. MMF and AZA are deemed suitable and have
shown efficacy in maintaining remission of lupus nephritis
[96]. Equivalence of MMF and AZA was reported in the
MAINTAIN Nephritis Trial, even though a trend towards
fewer renal flares in the MMF group (19% vs. 25% in
the AZA group) was reported [97]. More recently, in a
larger trial, MMF was superior to AZA with respect to
maintaining a renal response and preventing relapse in
patients with lupus nephritis [98].
B-cell depleting therapy with anti-CD20 antibody
rituximab (RTX) proved efficient in patients with active
SLE including patients with lupus nephritis, who were
nonresponsive to standard immunosuppressive therapy
[99]. In proof of the efficacy of RTX treatment in moder-
ately to severely active SLE and lupus nephritis, two large
multi-center trials were conducted. The EXPLORER trial
(moderate to severe active SLE) demonstrated no difference
in primary/secondary end points between RTX and
placebo. In a subgroup analysis a beneficial effect of RTX
was observed in the African-American/Hispanic subgroup[100]. In patients with proliferative lupus nephritis and
background immunosuppression (MMF) no difference was
noted when RTX was added with regard to safety and
efficacy (LUNAR trial) [101] even though opportunistic
infections are reported to be rather common in SLE pa-
tients related to RTX treatment [102]. Enthusiasm was also
dampened by reports on the development of progressive
multifocal leukoencephalopathy in SLE patients following
treatment with RTX [103].
Novel approaches with focus on targeted therapy have
been developed and are currently being evaluated in
clinical trials. Circulating B-lymphocyte stimulator (BLyS)
is elevated in SLE, and titers correlate with increased dis-
ease activity and elevated dsDNA antibody concentrations
[104]. Patients with serologically active SLE responded
significantly better to belimumab, an antibody that binds
to BLyS and inhibits its biological activity, plus standard
of care (SOC) than to SOC alone [105]. The efficacy of
belimumab was further corroborated in two large phase
III trials, BLISS 52 [106] and BLISS 76 [107]. In both trials,
belimumab met its primary efficacy end point and was
consequently approved by the FDA in the treatment of SLE
with the exception of severe active lupus nephritis or cen-
tral nervous system lupus. Further investigations addressed
to evaluate the role in active lupus nephritis are necessary.
Promising results have been obtained in a phase II
trial for epratuzumab, a humanized anti-CD22 antibody
[108,109]. Atacicept, a soluble receptor fusion protein,
neutralizes the activity of BLyS and a proliferation-inducing
ligand (APRIL) and their heterotrimers [110]. In a phase I
trial, atacicept was well tolerated and demonstrated a
dose-dependent reduction of immunoglobulin levels and
mature/total B cell numbers [111]. However, in patients
with active lupus nephritis, a phase II trial was terminated
due to an increased number of infections [109]. Further tri-
als assessing the efficacy and safety are currently ongoing.
In patients with highly active lupus nephritis with failure
of conventional therapy, short-term as well as prolonged
immuno-adsorption led to a significant reduction in pro-
teinuria and to sustained remission rates [112]. Autologous
stem cell transplantation achieved sustained clinical remis-
sions in patients refractory to conventional immunosup-
pressive treatment, even though this clinical benefit was
associated with increased mortality rates in most studies
conducted so far [113]. Intravenous immunoglobulins have
shown benefits in patients nonresponsive to other therapies
and as a steroid-sparing agent [114].
Conclusion
The histopathologic classification of lupus nephritis
still guides the therapy. In proliferative lupus nephritis
(III and IV), CYC and MMF have shown almost identical
therapeutic responses as induction therapy in large trials.
CSA might be an alternative to these immunosuppressive
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responding to initial treatment, multi-target therapy might
be an effective alternative. MMF seems to be superior to
AZA in maintaining remission. The role of RTX in the
treatment of lupus nephritis has to be further elucidated,
as well as the significance of novel therapeutic approaches
in the therapy of lupus nephritis.
Kidney disease in antiphospholipid syndrome
Introduction
Antiphospholipid syndrome (APS) is defined by the
association of vascular thrombosis potentially affecting
all segments of the vascular bed, complications during
pregnancy (including unexplained consecutive spontaneous
abortions, premature births because of severe preeclampsia,
eclampsia or placental insufficiency or unexplained death
before the 10th week of gestation), and the presence of
antiphospholipid antibodies (aPL), namely anticardiolipin
antibodies (aCL) and lupus anticoagulant (LAC) [115]. The
APS is classified as primary APS in the absence of associ-
ated autoimmune disease, whereas secondary APS is found
alongside other autoimmune disorders [116].
Histopathology/kidney involvement
Renal manifestations in the context of APS may result
from thrombosis occurring at any location in the renal
vasculature. Renal artery stenosis (RAS) is a common
complication of APS, leading to renovascular hypertension
[117]. In a retrospective study, patients with APS, RAS
and hypertension receiving oral anticoagulation with a
target trough International Normalized Ratio (INR) >3.0
had better blood pressure control and renal function
remained stable or improved, while in patients with an
INR <3.0 renal function significantly deteriorated and blood
pressure was poorly controlled [118]. Arterial hypertension
is a well-documented complication of APS. In a series of
patients with primary APS, a large proportion of patients
presented with hypertension, which was attributed to
biopsy-proven vascular nephropathy [119]. Kleinknecht
et al. reported that all patients had severe hypertension
and renal insufficiency in a small cohort of patients with
secondary APS due to SLE [120]. Thrombosis of the
renal vein and inferior vena cava usually presents with
nephrotic-range proteinuria in primary and secondary
APS [121], especially in those with circulating LAC
[122]. APSN refers to kidney damage caused by
intrarenal vascular damage and may be acute, in case of
the presence of thrombotic microangiopathy, and/or
chronic, in the case of arteriosclerosis, fibrous intimal
hyperplasia and focal cortical atrophy [119,123]. Throm-
botic microangiopathy is characterized by distinctive micro-
scopic and ultrastructural changes and clinical presentation
commonly includes hypertension, mild to nephrotic-range
proteinuria and renal impairment [119,123]. Tektonidouet al. examined kidney biopsies obtained from patients with
SLE with or without presence of aPL. APSN was detected
in almost 40% with aPL, compared with only 4.3% of
patients without aPL [16]. Fakhouri et al. examined 29
kidney biopsies of patients with APS [124]. In nine of these
biopsies predominant pathological features distinct from
ASPN were noted: membranous nephropathy (three cases),
minimal-change disease/focal segmental glomerulosclerosis
(three cases), mesangial c3 nephropathy (two cases), and
pauci-immune crescentic glomerulonephritis (one case).
Furthermore, a case of fibrillary glomerulonephritis in
a patient with APS was published recently [125]. Inter-
estingly, the presence of aPL in patients undergoing
renal transplantation significantly increases the risk of
renal vascular thrombosis and graft failure [126,127].
Therapy
Blood pressure control is the key intervention in the
treatment of APS-related renal involvement. Adequate
anticoagulation (if evidence of microthrombi is present)
has shown encouraging results in small cohorts and may
prevent progression to end-stage renal disease [128].
Evidence supporting immunosuppressive therapy in these
patients is limited to case series [125,129] and is not
routinely recommended in APS-related renal manifes-
tations. Contrasting, patients with catastrophic APS, which
is characterized by severe multiple organ dysfunction
in consequence of diffuse small vessel ischemia and
thromboses predominantly affecting the parenchymal
organs, usually receive a combination therapy, including
anticoagulation, steroids, intravenous immunoglobulins
and plasmapheresis, but despite this aggressive approach
mortality is still high [130].
Conclusion
Blood pressure control is mandatory in patients with
APSN. The role of anticoagulation with a target through
INR above 3.0 in patients with APSN and microthrombi to
prevent kidney function deterioration has to be elucidated
in further, larger studies.
Rheumatoid arthritis
Introduction
RA is characterized by persistent synovial, systemic inflam-
mation and autoantibodies (particularly to rheumatoid
factor and citrullinated peptides). Genetic as well as
environmental factors contribute to the risk of developing
RA [131]. Renal involvement is relatively common in
patients with RA.
Histopathology/kidney involvement
A study of renal biopsy specimens indicated that mesangial
glomerulonephritis is the predominant histopathologic
finding in RA, followed by amyloidosis, membranous
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minimal-change nephropathy and acute interstitial
nephritis [17]. Development of membranous nephropathy
is related either to therapy with disease modifying anti-
rheumatic drugs (DMARDs), in particular gold thiomalate,
D-penicillamine and bucillamine [132], and anti-TNF alpha
therapy, such as etanercept and adalimumab [133,134], or
rarely occurs concomitant with RA [135]. Secondary AA
amyloidosis was prevalent in 5.8% of patients with RA and
was accompanied by a shortened life expectancy [136].
Deposition of amyloid in renal tissue correlated signifi-
cantly with parameters of renal function [132], while a lack
of amyloid deposition in the glomerulus may characterize
subjects with stable renal function [137]. Mesangial
glomerulonephritis is probably related to RA itself, since
its occurrence was associated with higher titers of rheuma-
toid factor (RF) when compared with RA patients without
nephropathy. Deposition of mesangial IgA correlated with
the duration of RA and elevated serum IgA levels, whereas
mesangial IgM deposition was correlated with serum levels
of IgM class RF [138]. In addition, single reports reveal the
presence of FSGS [139] and fibrillary glomerulonephritis
[140] in RA patients. Anti-TNF alpha therapy can be causa-
tive for the development of necrotizing crescentic glomer-
ulonephritis and proliferative lupus nephritis [141,142].
Besides the renal side effects of gold salts, D-penicillamine
and bucillamine, CSA as another DMARD has a serious
potential for renal toxicity, which is manifested primarily in
a decline in creatinine clearance [143].
Therapy
Improvement of clinical and laboratory parameters
was achieved in most cases after drug withdrawal and
in case of necessary initiation of immunosuppression
[133,134,142,143]. In patients with amyloid deposition,
etanercept treatment reduced proteinuria as well as
serum amyloid A. Furthermore, it entailed a decrease
in serum creatinine in patients with creatinine values
<2.0 mg/dl at the onset of amyloidosis [144].
Conclusion
Therapy related deterioration of kidney function has to be
excluded in patients with RA. In addition, the persisting
inflammation can lead to deposition of amyloid. Thus,
adequate therapy to reduce disease activity may be effective
in preventing this late-onset complication. Specific thera-
peutic interventions should be tailored to the underlying
histologic kidney involvement.
Conclusion and future directions
Renal involvement is frequently present in CTDs and
has variable phenotypes. Since there is a steady
increase of knowledge regarding the pathophysiology
behind auto-immune disorders, more specific therapeuticapproaches have been developed and are currently in
clinical trials.
Acute or chronic TIN is the predominant kidney biopsy
finding in Sjögren syndrome. Kidney function normalizes
in most cases after corticosteroids are initiated [2,6]. In
addition, several glomerular lesion patterns have been
described in Sjögren syndrome.
Results from hematopoietic stem cell transplantation
(HSCT) in SSc are promising. Current studies, namely
the SCOT and ASTIS trials, have completed patient
recruitment and the first results are expected soon
[145]. The ASSIST trial clearly depicted the efficacy of
HSCT in patients with scleroderma, since all 10 patients
in the HSCT-group improved when compared to none
in the CYC–treated cohort [146]. In addition, endothelin
receptor antagonists in combination with dual blockade
of the renin-angiotensin-aldosterone system (RAAS) sig-
nificantly reduced proteinuria and stabilized the serum
creatinine level after an initial increase in a patient with
SRC [147]. Despite efficacy in patients with pulmonary
arterial hypertension in SSc [148], trials with the aim to
show benefits of endothelin receptor antagonists in SRC
have yet to be conducted.
Diverse glomerular alterations and rhabdomyolysis have
been reported in patients with auto-immune myopathies.
Guided therapy with the aim to treat the underlying disease
improves kidney function in most cases.
In SLE, new therapeutic approaches have gained atten-
tion. One of these novel agents is belimumab, an inhibitor
of serum BLyS, which was recently approved by the FDA
for treatment of SLE with the exception of active lupus
nephritis and central nervous system involvement. A
randomized, controlled trial with inclusion of active lupus
nephritis is currently being designed. Furthermore, BLyS
inhibition may also be effective in the treatment of PSS,
since patients with Sjögren syndrome exhibit increased
BLyS levels [149]. In patients with SLE, B-cell depleting
therapy with RTX was effective in a larger cohort including
patients with lupus nephritis [99], and efficacy was further-
more confirmed in a recent meta-analysis evaluating
patients with refractory lupus nephritis [150]. However,
RTX failed to show superiority in two large phase III
trials with patients either presenting without renal
involvement (EXPLORER) or with renal involvement
(LUNAR) [100,101] even though a post hoc analysis of
the EXPLORER trial indicated that RTX-treated patients
achieved lower disease activity without a subsequent severe
disease flare when compared to those treated with
placebo [151]. Persistent B-cell presence was associated
with no clinical response following RTX treatment
[152]. In addition, physicians should be aware of severe
infectious complications following RTX treatment in
SLE patients [102,103]. Despite other strategies, such as
immunoglobulin administration, immuno-adsorption and
Table 4 Suggested kidney biopsy indications in connective tissue diseases
Biopsy indication rapid deterioration of renal function (exclude post renal and pre renal disorders first)
Biopsy indication proteinuria >1 g/d (measured by collecting urine; collection over the course of a 24-hour period; to begin urine collection,
the patient voids and discards the urine already in the bladder, afterwards urine for the next 24 hours has to be collected
to ensure accurate results), if other causes of proteinuria are ruled out
the EULAR/ERA-EDTA recommendations for the management of lupus nephritis suggest performing a renal biopsy if
reproducible proteinuria >0.5 g/d is present (especially with glomerular hematuria and/or cellular cases) [72]
Biopsy indication nephritic urine sediment (red blood cell casts) with deterioration of kidney function (estimated GFR <60 ml/min)
if pre-existing impaired renal function is ruled out
Consider re-biopsy increase in proteinuria/serum creatinine despite ongoing immunosuppressive therapy (exclude post-renal and pre-renal
disorders first); consider a repeat kidney biopsy due to potential phenotype change (for example, lupus nephritis)
Biopsy indication suspected interstitial nephritis, findings of white blood cell casts; leukocyturia (due to proton pump inhibitors,
non-steroidal anti-rheumatic drugs, Sjögren syndrome, rheumatoid arthritis, and so on)
Biopsy indication diagnostic approach in case of uncertainties, when kidney involvement is suspected,
but absolute indications are not met
Renal biopsy suggestions differ between centers due to local preferences. General recommendations are difficult to define and we would consider higher levels of
proteinuria (>1 g/d) compared to the EULAR/ERA-EDTA recommendations as biopsy indication for patients with lupus nephritis in our center.
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one alternative in refractory SLE [99].
APS-related renal manifestation potentially affects any
segment of the vascular bed and is commonly accom-
panied by arterial hypertension. Blood pressure control
is crucial, whereas the role and the target level of oral
anticoagulation needs to be further elucidated. Chronic
inflammation, as well as drug related adverse effects, is
causative of kidney involvement in RA. Etanercept has
shown encouraging results in reduction of serum amyloid
A in amyloidosis and patients with a baseline serum
creatinine below 2 mg/dl tended to show a benefit
following TNF-alpha inhibition [144].
Based on studies in non-diabetic nephropathy, patients
with renal involvement in CTDs should receive RAAS
blocking agents once proteinuria is >1 g/day [149,150].
Renal function needs to be monitored as well as serum
potassium levels and blood pressure. In chronic kid-
ney disease in the pre-dialysis state the lowering of
LDL-cholesterol safely reduced the risk of major
atherosclerotic events [153]. Accelerated atherosclerosis is
a common finding in patients with chronic inflammation
and in CTDs in particular [154]. Thus, modification of the
risk factors contributing to the evolution of cardiovascular
disease is crucial in these patients. Moreover, adher-
ence to therapeutic advice may be an underestimated
problem, since a recent study indicated that only
one-quarter of patients with SLE had an adherence
rate ≥80% [155]. In addition, counselling against
smoking should be mandatory in patients with SLE
and RA [156].
In summary, renal manifestations of CTDs are frequent.
Renal biopsy to ensure diagnosis is necessary in most
patients presenting with deterioration of renal function,
increase of proteinuria or signs of nephritic syndrome(summarized in Table 4). An interdisciplinary approach to
optimize treatment is the aim for patients with CTDs.
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